Business
Patent Litigation Brought by Decision Diagnostics Subsidiaries against Johnson & Johnson/Lifescan Moves Toward Major Ruling
Patent Litigation Brought by Decision Diagnostics Subsidiaries against Johnson & Johnson/Lifescan Moves Toward Major Ruling.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Hearing in Federal Court on November 17 Sets Stage for Conclusion of CaseLOS ANGELES, CA / ACCESSWIRE / September 21, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator, and the exclusive worldwide sales, service, and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's (\"J&J\") LifeScan OneTouch Ultra family of glucose testing meters, and the recently released GenSure!™ test strip for the developing world, and the post-development GenChoice!™ test strips to be targeted to international markets and (later to) U.S. markets, and, finally, the upcoming GenPrecis Precision system, which is expected to set new standards in at-home diabetes testing, today reports on two consequential updates in its most recent battle with two divisions of pharmaceutical industry giant Johnson + Johnson, who, in September 2011, began a series of lawsuits based on false and, as ultimately demonstrated, frivolous legal allegations of patent and trademark infringement.On September 18, 2017, J&J/Lifescan filed its last pleadings in support of their Motion for Summary Judgement in the litigation brought by DECN subsidiaries. This pleading now sets the clock for a ruling by the Federal judge in Nevada Federal court. A November 17, 2017 date has been set for final verbal arguments in these matters, with a ruling expected shortly thereafter. DECN has sued J&J/Lifescan in Federal court in Las Vegas Nevada and has made claims for $400-700 million, as further outlined in the lawsuit.Keith Berman, CEO of Decision Diagnostics and President of its PharmaTech Solutions subsidiary, commented, \"This lawsuit we brought against Johnson & Johnson/Lifescan is a natural progression of the business and the patent battles we have had dating back to 2011. While J&J/Lifescan have employed guerrilla warfare strategies (or in legal terms, tortuous interference) such as writing threatening letters to our clients, the clients of our clients and to independent pharmacies amending their franchise contracts to add punitive clauses keeping large chain pharmacies and other stores from buying DECN products. DECN has nonetheless endured and with the lawsuit and recent challenges, we have gained a...